VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MDGL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MDGLMadrigal Pharmaceuticals, Inc.
$399.63$9.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. MDGL
  4. Financial Ratios

Madrigal Pharmaceuticals, Inc. (MDGL) Financial Ratios

Latest Ratios: P/E Ratio -77.9x · EV/EBITDA N/A · ROE -42.5%. (2003–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

MDGL Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$9.2B$13.1B$6.6B$4.3B$5.0B$1.4B$1.7B$1.4B$1.7B$1.1B$78M
Enterprise Value$9.4B$13.2B$6.6B$4.3B$4.7B$1.4B$1.7B$1.4B$1.2B$932M$37M
P/E Ratio →-77.92——————————
P/S Ratio6.4513.6336.44————————
P/B Ratio14.8821.688.7010.6725.207.157.163.373.506.172.13
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

MDGL EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—13.7936.55————————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

MDGL Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin94.1%94.1%96.5%————————
Operating Margin-31.3%-31.3%-276.4%————————
Net Profit Margin-30.1%-30.1%-258.6%————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-42.5%-42.5%-80.3%-124.0%-150.1%-110.9%-61.6%-18.8%-10.0%-28.5%-60.8%
ROA-25.0%-25.0%-55.4%-74.5%-92.9%-86.3%-55.5%-18.1%-9.7%-26.7%-48.2%
ROIC-29.4%-29.4%-62.4%-168.7%-576.6%-104.7%-55.5%-18.0%-13.4%-161.9%-234.2%
ROCE-32.9%-32.9%-71.4%-99.0%-132.5%-111.0%-62.8%-21.2%-12.3%-29.2%-90.3%

MDGL Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.590.590.160.290.250.000.000.00———
Debt / EBITDA———————————
Net Debt / Equity—0.260.030.04-1.43-0.18-0.22-0.11-1.01-1.05-1.11
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-11.92-11.92-30.76-28.39-73.51—————-21.63

MDGL Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio4.014.016.105.383.123.546.1317.5257.4619.108.58
Quick Ratio3.773.775.905.383.123.546.1317.5257.4619.108.58
Cash Ratio3.173.175.475.353.103.526.1017.4757.2919.058.44
Asset Turnover—0.760.17————————
Inventory Turnover0.750.750.18————————
Days Sales Outstanding—51.21109.06————————

MDGL Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$22M$21M$19M$17M$17M$15M$15M$15M$12M$5M

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Sustainability of operating profit

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Price Revenue Durability Not Earnings

Based on reported figures, MDGL trades at 9.62 times sales and 14.89 times book while trailing P/E is negative at -31.14, indicating the market is capitalizing revenue growth rather than demonstrated earnings power today.

A negative trailing P/E alongside a 9.62 price-to-sales multiple suggests investors are paying for the commercial revenue ramp rather than reported earnings, which is typical of a company only recently turning operating-positive. The 14.89 price-to-book multiple reflects an equity base heavily reduced by an accumulated deficit of roughly $2.2B, so book value offers little valuation anchor. Investors should monitor whether the 2026Q3 operating profit proves repeatable before the multiple can be reconciled to sustained earnings.

Operating Turn Rests on a Single Quarter

According to the reported income ratios, MDGL's operating margin moved from -29.8% in 2026Q1 to 13.0% in 2026Q3, but the improvement follows two loss-making quarters and remains unproven as a trend.

The swing from deeply negative operating margins to 13.0% suggests operating leverage is beginning to flow through as revenue scales, with net margin of 12.9% tracking closely. However, gross margin compressed from 96.7% to 89.0% before recovering to 91.2%, which may indicate mix or pricing pressure as the product base broadens. Earning power should be judged on a sustained run of positive quarters rather than the latest print.

Returns Recovering From Deeply Negative Territory

Based on reported figures, MDGL's ROIC improved from -13.0% in 2025Q3 to 8.0% in 2026Q3 and ROE moved to 9.6%, yet both remain low against a multi-year negative trend.

The move to positive ROIC and ROE suggests returns are moving in the right direction, but ten quarters of prior negative returns mean the trend is recent and unproven. The improvement appears driven primarily by margin recovery rather than capital efficiency, since asset turnover remains low at 0.32. Investors should watch whether ROIC can hold above its cost of capital through a full operating cycle.

Strong Current Ratio Masks Volatile Cash Base

As reported in the balance sheets, MDGL's current ratio compressed from 8.72 in 2024Q2 to 3.05 in 2026Q3, while the quick ratio of 2.78 still indicates ample short-term coverage.

Even after compression, a 3.05 current ratio and 2.78 quick ratio suggest the company holds substantial liquid assets relative to near-term obligations, with inventory dependence appearing minimal. The sharp decline from 8.72 over ten quarters may reflect rising current liabilities alongside commercial scale-up. Under severe stress, liquidity would depend heavily on cash balances that have swung materially, so investors should monitor cash levels in future filings.

Debt Rising but Coverage Now Positive

Based on reported figures, MDGL's debt-to-equity rose from 0.14 to 0.56 and interest coverage turned to 7.87 in 2026Q3 after negative readings through 2026Q2.

Debt has roughly tripled while equity contracted before recovering, lifting leverage to a moderate level, and the reported D/EBITDA of 6.28 in 2026Q3 is elevated relative to a conventional comfort threshold. The shift to positive interest coverage suggests debt service has become manageable on current operating profit, but this rests on one quarter of earnings. Refinancing and covenant exposure cannot be assessed from the supplied data and warrant further investigation.

Single-Quarter Turn May Not Persist

The most commonly misapplied metric here is trailing ROE, since MDGL's 9.6% reading in 2026Q3 relies on a single profitable quarter against ten quarters of negative returns and a shrinking equity base.

For a pre-profit commercial biotech, ROE is distorted by a small and recently rebuilt equity denominator and by the accumulated deficit, so a positive print can overstate durable returns. Operating cash flow has been erratic and working capital swings dominate quarterly results, which suggests a cash-based or revenue-run-rate measure would be more informative than headline ROE. Investors should evaluate sustained positive operating margins and cumulative free cash flow over several quarters before treating the return improvement as structural.

Download Financial Ratios Data

Includes 30+ ratios · 23 years · Updated daily

Consensus & Technical Research Suite
Open MDGL Terminal

MDGL Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MDGL — Frequently Asked Questions

Quick answers to the most common questions about buying MDGL stock.

What is Madrigal Pharmaceuticals, Inc.'s P/E ratio?

Madrigal Pharmaceuticals, Inc.'s current P/E ratio is -77.9x. The historical average is 2.2x.

What is Madrigal Pharmaceuticals, Inc.'s ROE?

Madrigal Pharmaceuticals, Inc.'s return on equity (ROE) is -42.5%. The historical average is -76.7%.

Is MDGL stock overvalued?

Based on historical data, Madrigal Pharmaceuticals, Inc. is trading at a P/E of -77.9x. Compare with industry peers and growth rates for a complete picture.

What are Madrigal Pharmaceuticals, Inc.'s profit margins?

Madrigal Pharmaceuticals, Inc. has 94.1% gross margin and -31.3% operating margin.